Everest Medicines to Announce Full-Year 2020 Financial Results on March 22, 2021 Shanghai, China – March 18, 2021 – Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that it will report financial results for the full year ended December 31, 2020 and provide a business update on March 22, 2021. Conference Call Information A live conference call will be hosted on March 22, 2021 at 9:00 a.m. China Standard Time (March 21, 2021 at 9:00 p.m. Eastern Time). Details are as follows: Conference ID 7234522#
About Everest Medicines Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of eight potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development. The Company’s therapeutic areas of interest include oncology, autoimmune disorders, cardio-renal diseases and infectious diseases. For more information, please visit its website at www.everestmedicines.com. For further information, please contact: Everest Medicines Media in US and Europe:
ICR Asia |